JP2022550345A5 - - Google Patents

Info

Publication number
JP2022550345A5
JP2022550345A5 JP2022519226A JP2022519226A JP2022550345A5 JP 2022550345 A5 JP2022550345 A5 JP 2022550345A5 JP 2022519226 A JP2022519226 A JP 2022519226A JP 2022519226 A JP2022519226 A JP 2022519226A JP 2022550345 A5 JP2022550345 A5 JP 2022550345A5
Authority
JP
Japan
Prior art keywords
optionally
amino acid
signaling molecule
cancer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022519226A
Other languages
English (en)
Japanese (ja)
Other versions
JP7793511B2 (ja
JP2022550345A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/052764 external-priority patent/WO2021062184A1/en
Publication of JP2022550345A publication Critical patent/JP2022550345A/ja
Publication of JP2022550345A5 publication Critical patent/JP2022550345A5/ja
Priority to JP2025259819A priority Critical patent/JP2026048868A/ja
Application granted granted Critical
Publication of JP7793511B2 publication Critical patent/JP7793511B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022519226A 2019-09-26 2020-09-25 Ｐｄ－ｌ１標的化キメラタンパク質及びその使用 Active JP7793511B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025259819A JP2026048868A (ja) 2019-09-26 2025-12-17 Ｐｄ－ｌ１標的化キメラタンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906447P 2019-09-26 2019-09-26
US62/906,447 2019-09-26
PCT/US2020/052764 WO2021062184A1 (en) 2019-09-26 2020-09-25 Pd-l1 targeted chimeric proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025259819A Division JP2026048868A (ja) 2019-09-26 2025-12-17 Ｐｄ－ｌ１標的化キメラタンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2022550345A JP2022550345A (ja) 2022-12-01
JP2022550345A5 true JP2022550345A5 (enExample) 2023-10-31
JP7793511B2 JP7793511B2 (ja) 2026-01-05

Family

ID=75166458

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519226A Active JP7793511B2 (ja) 2019-09-26 2020-09-25 Ｐｄ－ｌ１標的化キメラタンパク質及びその使用
JP2025259819A Pending JP2026048868A (ja) 2019-09-26 2025-12-17 Ｐｄ－ｌ１標的化キメラタンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025259819A Pending JP2026048868A (ja) 2019-09-26 2025-12-17 Ｐｄ－ｌ１標的化キメラタンパク質及びその使用

Country Status (7)

Country Link
US (1) US20230002493A1 (enExample)
EP (1) EP4034565A4 (enExample)
JP (2) JP7793511B2 (enExample)
CN (1) CN114761430A (enExample)
AU (1) AU2020353660A1 (enExample)
CA (1) CA3151928A1 (enExample)
WO (1) WO2021062184A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
EP4367144A4 (en) * 2021-07-08 2025-07-02 Orionis Biosciences Inc CHIMERIC INTERLEUKIN-1 ALPHA PROTEIN
KR20240099460A (ko) 2021-11-11 2024-06-28 리제너론 파아마슈티컬스, 인크. Cd20-pd1 결합 분자 및 이의 사용 방법
EP4727977A2 (en) * 2023-07-14 2026-04-22 Ohio State Innovation Foundation Cd276 antibody and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907424E (pt) * 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
CA2712432C (en) 2008-01-29 2018-09-25 Ablynx N.V. Methods to stabilize single variable domains
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20140079691A1 (en) * 2012-09-20 2014-03-20 Anaptysbio, Inc. Thermostable antibody framework regions
SG10201807625PA (en) * 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
US11661455B2 (en) * 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN116769054A (zh) * 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
EP3596116B1 (en) * 2017-03-16 2023-09-06 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
JP7679196B2 (ja) * 2017-06-08 2025-05-19 ブラック ベルト セラピューティクス リミテッド Ｃｄ３８調節抗体
GB201710973D0 (en) * 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
EP3664829A4 (en) * 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
JP7404252B2 (ja) * 2017-11-08 2023-12-25 ヤフェイ シャンハイ バイオロジー メディスン サイエンス アンド テクノロジー カンパニー リミテッド 生体分子のコンジュゲートおよびその使用
US11440943B2 (en) * 2019-03-28 2022-09-13 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins

Similar Documents

Publication Publication Date Title
JP2022550345A5 (enExample)
US11136413B2 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
JP2018523493A5 (enExample)
JP2021531754A5 (enExample)
JP2022515318A5 (enExample)
RU2018139339A (ru) Новые биспецифические полипептиды против cd137
JP2021531764A5 (enExample)
JP2017149720A5 (enExample)
HRP20230787T1 (hr) Anti-muc1 antitijelo
JP2019529373A5 (ja) 抗Ｔｉｍ−３抗体
JP2021521275A5 (enExample)
JP2022534837A5 (enExample)
HK1217958A1 (zh) 四价双特异性抗体
JP2019509055A5 (enExample)
JP2015506912A5 (enExample)
JP2013505732A5 (enExample)
JP2018522888A5 (enExample)
JP2024522949A5 (enExample)
JP2021522347A5 (enExample)
JP2022532812A5 (enExample)
CN115894701A (zh) 结合cd3的抗体及其用途
JP2022512891A5 (enExample)
CN121758617A (zh) 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途
JP2020502233A5 (enExample)
WO2024114676A1 (zh) Cldn18.2/4-1bb结合蛋白及其医药用途